TGFB1 and neoplasm: Taken together, these results indicate that the loss of TGFβ tumor-suppressive responses in patients harboring MEN1 mutations leading to MEN1 degradation could be circumvented by blocking the proteasome degradation pathway, thereby offering new therapeutic opportunities for patients with melanoma.